Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabozantinib + ipilimumab + nivolumab
- Development stage
- Phase 3
- Lead developer
- Exelixis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Cabozantinib + ipilimumab + nivolumab is a triplet combination therapy that combines a tyrosine kinase inhibitor (cabozantinib) with two immune checkpoint inhibitors (ipilimumab and nivolumab). This combination has been studied primarily for advanced renal cell carcinoma (RCC) and other genitourinary tumors. The triplet therapy works through complementary mechanisms: cabozantinib inhibits multiple receptor tyrosine kinases involved in tumor growth and angiogenesis (including MET, VEGFR, and the TAM family of kinases), while nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) promote antitumor immune responses through different but complementary immune checkpoint inhibition pathways.
- Other names
- CaboNivoIpicabozantinib + nivolumab + ipilimumab
02
Targets
AXL (AXL receptor tyrosine kinase)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)MET (Mesenchymal-epithelial transition factor receptor)PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)TAM (TAM receptor tyrosine kinases)
Beyond the preview
Go deeper on cabozantinib + ipilimumab + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabozantinib + ipilimumab + nivolumab.